221 related articles for article (PubMed ID: 34454906)
21. Combination of Neutrophil-to-Lymphocyte Ratio and Red Cell Distribution Width With Serum Tumor Markers for the Differential Diagnosis of Breast Cancer and its Association With Pathological Features and Molecular Types.
Zou H; Liu SH; Yang R; Wu XJ; Cao YP; Huang HF
Clin Breast Cancer; 2022 Jun; 22(4):e526-e535. PubMed ID: 34963613
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
23. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study.
Fan S; Xie X; Shen Y; Wang W; Gu X; Yao Z
Medicine (Baltimore); 2022 Aug; 101(32):e30011. PubMed ID: 35960055
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
25. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
26. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
[TBL] [Abstract][Full Text] [Related]
27. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
Wen Z; Huang Y; Ling Z; Chen J; Wei X; Su R; Tang Z; Wen Z; Deng Y; Hu Z
Dis Markers; 2020; 2020():4716793. PubMed ID: 33488842
[TBL] [Abstract][Full Text] [Related]
28. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
29. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
30. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer.
Pronk LC; Stoter G; van Putten WL; de Wit R
J Cancer Res Clin Oncol; 1997; 123(2):128-32. PubMed ID: 9030253
[TBL] [Abstract][Full Text] [Related]
31. Leukocyte alkaline phosphatase, CA15-3, CA125, and CEA in cancer patients.
Walach N; Gur Y
Tumori; 1998; 84(3):360-3. PubMed ID: 9678617
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients.
Li X; Dai D; Chen B; Tang H; Xie X; Wei W
Dis Markers; 2018; 2018():9863092. PubMed ID: 29854028
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
35. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
36. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
Robertson JF; Jaeger W; Syzmendera JJ; Selby C; Coleman R; Howell A; Winstanley J; Jonssen PE; Bombardieri E; Sainsbury JR; Gronberg H; Kumpulainen E; Blamey RW
Eur J Cancer; 1999 Jan; 35(1):47-53. PubMed ID: 10211087
[TBL] [Abstract][Full Text] [Related]
37. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
38. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
39. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of preoperative serum tumor markers CEA, CA19-9, CA125, and CA15-3 in surgically treated urachal cancer.
Stokkel LE; van Rossum HH; van de Kamp MW; Boellaard TN; Bekers EM; Kok NFM; van Rhijn BWG; Mertens LS
Urol Oncol; 2023 Jul; 41(7):326.e17-326.e24. PubMed ID: 36813613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
